Focus Stocks
Is Novartis Reversing?
Published on Thursday, 02 February 2012 04:03 Written by Danny Miller
New York, February 2nd (TradersHuddle.com) - Shares of Novartis AG (NYSE:NVS) closed the trading
day higher by $1.13 or 2.08% from its previous close. Novartis' shares price action formed what is considered to be a
doji close, where the open and close prices are very close to each other, mainly signaling an indecision between buyers and sellers.
Novartis AG (NYSE:NVS) manufactures pharmaceutical and consumer healthcare products. The Company produces branded and generic pharmaceuticals for a number of uses like cardiovascular, respiratory and infectious diseases. The Basel, Switzerland based company also offers over the counter vision and animal health products.
Novartis' current stock range is defined by a trough, which marks calculated support at $54.07 and by a peak that marked the resistance point at $58.37. These levels are closely watched by traders managing their positions.
Traders wanting to establish a position in Novartis or traders that are already holding the stock can use the doji close to their advantage, since the pattern present a short term pause in the stock's price action. This pause results in an entry point for traders depending of which way the stock resolves this short term indecision.
Doji are important candlesticks that provide information on their own and as components in a number of important patterns. Doji form when a security's open and close are virtually equal. The length of the upper and lower shadows can vary and the resulting candlestick looks like a cross, inverted cross or plus sign. Alone, doji are neutral patterns.
Any bullish or bearish bias is based on preceding price action and future confirmation. In the case of Novartis, given that the stock finished the session higher, bulls should monitor their positions for confirmation that stock will continue higher by taking today's intraday high. Below a Doji illustration:

Related Articles
- New Ratings: NVS, SNY, CYS
- Novartis drug Afinitor® approved by FDA as first medication to treat patients with non-cancerous kidney tumors associated with TSC
- Bulls taking Control of Novartis?
- Bulls and Bears on the Trenches of Novartis
- Bears Appeared on Novartis
- Bulls and Bears on the Trenches of Novartis
- Novartis Higher With High Volume
Related Partner Headlines
- Novartis AG ADR (NVS): Today's Featured Health Care Loser - TheStreet.com
- Novartis AG ADR (NVS): Today's Featured Health Care Loser - TheStreet.com
- Novartis Stock To Go Ex-dividend Monday (NVS) - TheStreet.com
- UPDATE: Bank of America Downgrades Novartis to Underperform - Benzinga
- From Earlier: FDA Approves Novartis Drug Gleevec Label Recommending Extending Treatment to Three Years for Certain GIST Patients After Surgery - Benzinga
- Novartis AG (NVS): Today's Featured Health Care Winner - TheStreet.com
- Novartis AG (NVS): Today's Featured Drugs Loser - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Capital One: Financial Winner - TheStreet.com -
Foot Locker Stock Hits New 52-Week High (FL) - TheStreet.com -
Cooper Reaches New 52-Week High (CBE) - TheStreet.com -
Lehman Brothers Gets a Pass From SEC: Report - TheStreet.com -
Meritage Homes Reaches New 52-Week High (MTH) - TheStreet.com -
Meritage Homes Reaches New 52-Week High (MTH) - TheStreet.com -
New Fear Emerges Regarding Europe - TheStreet.com -
AmTrust Financial Services Stock Hits New 52-Week High (AFSI) - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:20PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:4:28PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
Susser Holdings Updates Investor Presentation -
Arbitron Inc. Declares Quarterly Dividend; Holds Annual Stockholders' Meeting -
Katahdin Bankshares Corp. Announces Dividend -
Infoblox Reports Third Quarter of Fiscal 2012 Results -
Versant Announces Quarterly Revenues of $3.8 Million -
China Kanghui Holdings Reports First Quarter 2012 Financial Results -
KEMET to Present at KeyBanc Capital Markets Industrial, Automotive & Transportation Conference -
The Chefs' Warehouse, Inc. to Present at the Jefferies 2012 Global Consumer Conference









